BMC Neurology

Objective To estimate the mortality proportion among patients with severe traumatic brain injury (sTBI) and to assess variation in mortality according to geographical region, study characteristics, patient populations, and mortality assessment time points. Design Systematic review and meta-analysis. Data sources PubMed/MEDLINE, Embase, Scopus, Web of Science, Google Scholar, and Cochrane Library were searched from database inception to January 2026. Eligibility criteria Studies reporting mortality among patients with severe TBI were eligible. Severe TBI was defined as a Glasgow Coma Scale (GCS) score of [&le;]8, equivalent to GCS <9 or GCS 3-8. Studies involving mixed TBI severity were included only when data for patients with severe TBI could be separately extracted. Data extraction and synthesis Two reviewers independently screened studies, extracted data, and assessed methodological quality. Mortality proportions were pooled using a random-effects model. Statistical heterogeneity was assessed using Cochran's Q and the I2 statistic. Subgroup and sensitivity analyses were undertaken where sufficient data were available. Results Twenty-five studies comprising 12,829 patients with severe TBI were included in the systematic review. Across studies, 5,550 deaths were reported. Mortality proportions ranged from 17.5% to 71.1%. The pooled mortality proportion was 40.6% (95% CI 35.7% to 45.7%), with substantial heterogeneity (I2=96.8%, p<0.001). Mortality varied considerably according to geographical region and timing of outcome assessment, with higher estimates generally observed in African settings and at longer follow-up periods. Conclusion Mortality among patients with severe TBI remains substantial, with approximately two in five patients dying across the included studies. However, the very high heterogeneity indicates that the pooled estimate should not be interpreted as a universal mortality risk. Differences in healthcare resources, patient characteristics, injury severity, management practices, and mortality assessment time points may contribute to the observed variation.

Background: Temporary 60-day percutaneous peripheral nerve stimulation (PNS) can relieve pain in refractory occipital neuralgia (ON), but whether it alters acute healthcare utilization relative to the natural trajectory of the disease is unknown, because prior studies have lacked a concurrent comparator. Methods: We performed a secondary analysis of prospectively collected data from a tertiary interventional pain center. Adults with medically refractory ON (primary diagnosis occipital neuralgia, ICD-10-CM M54.81) who underwent 60-day occipital PNS (n = 42) were compared with concurrent patients who were clinically eligible for PNS but were denied insurance authorization and continued optimized non-PNS management (usual care; n = 63). Headache-related emergency department (ED) encounters - index (occipital neuralgia) and non-index (other headache/facial-pain diagnoses) - were ascertained over the 12 months before and after the treatment window via the electronic record and the statewide health information exchange. Patients were 1:1 propensity-matched on a priori confounders (age, sex, baseline total headache-related ED utilization, HIT-6, and baseline headache-medication use). The primary analysis was a difference-in-differences (DiD) comparison of the change in headache-related ED utilization, reported as the additive difference (Hodges-Lehmann estimate, distribution-free 95% CI) and, alongside, as a multiplicative rate ratio (RR). Results: Thirty-six matched pairs were well balanced. Baseline headache-related ED utilization was nearly identical between matched groups (6.3 vs. 6.2 visits/year). Over the following year, PNS patients' utilization fell to 2.5 while usual-care patients' rose to 6.9. The DiD was 5.0 fewer headache-related ED visits per patient (95% CI 3.0-6.0; p < 0.001), corresponding to a rate ratio of 0.36 (95% CI 0.27-0.48; p < 0.001). Results were consistent in the full sample, in covariate-adjusted models, and after excluding controls denied for incomplete conservative-therapy trials. The effect was driven by non-index headache visits. Conclusions: Relative to a concurrent, matched usual-care cohort whose headache related ED utilization rose over time, 60-day occipital PNS was associated with a substantial reduction in acute-care use, strengthening the case for a role of PNS on healthcare utilization in refractory ON.

Many pathological conditions, including chronic pain (CP), can impair cognitive functions. These functions are essential for adapting and evolving in concordance with the environment, which are key processes for coping with CP. However, in CP centers, cognitive assessment is rarely included in CP patient follow-up due to a lack of time, appropriate tools, or trained health professionals. To fill this gap, our team developed EasyCog, a digital tool that enables rapid self-assessment of cognitive functions. It enables cognitive evaluation without an experimenter's help, thanks to speech recognition powered by an artificial neural network. In the initial validation steps, we established normative values for 7 cognitive functions on a cohort of 76 healthy subjects. Because EasyCog includes tests comparable to the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE), we assessed its reliability against available normative values. To assess its specificity, we compared data from healthy subjects with 15 subjects with mild cognitive impairment (MCI) and 15 age-matched CP patients selected from a medical center. Finally, we tested EasyCog's test-retest reliability by repeating sessions at different time intervals. EasyCog showed excellent sensitivity to age-related decline, similar to MoCA normative values. Several cognitive functions were significantly and differentially impaired in MCI subjects and CP patients compared to normative values in healthy subjects, confirming good specificity. Finally, test-retest analysis showed no effect at a 4-month interval. In conclusion, EasyCog appears to be a convenient and reliable numeric tool for rapidly assessing and monitoring cognitive functions in patients.

Introduction: Hematoma expansion is a main cause of early worsening after spontaneous intracerebral hemorrhage (ICH). Many hospitals in low income countries have no invasive pressure monitoring and no automated pupillometer. Staff use the Glasgow Coma Scale (GCS) and a penlight to check the pupils, and pupil changes seen with a penlight usually come late. The speed of pupil constriction may change earlier, and smartphones record video fast enough to measure it. Methods and analysis: This will be a single-centre prospective cohort study of 120 adults with ICH on non-contrast computed tomography (NCCT) who arrive within 24 hours of symptom onset. At admission and every 6 hours until 48 hours, we will record a 6 second smartphone video of each eye reacting to a flash, using an eyecup that blocks ward light. Open-source software will measure the pupil diameter in every frame. The main measure is constriction velocity (CV). The primary outcome is hematoma expansion (an increase of more than 6 mL or more than 33%) on NCCT at 24 hours. Secondary outcomes are a fall of 2 or more GCS points within 48 hours and in-hospital death. The primary analysis estimates the area under the receiver operating characteristic curve for the percentage fall in CV from each patient's first recording. Ethics and dissemination: Patients or their legal representatives will give written consent. Results will be submitted to a peer-reviewed journal, and the analysis code will be made public.

Background: Depression symptoms following traumatic brain injury (TBI) are common and strongly associated with adverse overall outcomes in military service members, veterans, and civilians. Cognitive behavioral therapy for depression (CBT-D) is considered a first-line treatment for depression symptoms in many contexts. However, costs associated with CBT-D can be substantial, and there are insufficient numbers of providers trained to perform CBT-D. In contradistinction, digital therapeutic interventions such as smartphone apps have virtually unlimited availability and low per-patient costs. However, evidence for efficacy of digital interventions providing CBT-D in the context of TBI is limited. The aims of this study were to design, develop, and test a novel smartphone app to provide CBT-D intended for military service members with depression symptoms and history of mild TBI. Results: We designed a novel smartphone app featuring digital avatar coaches to provide CBT-D intended for military service members with depression symptoms and history of mild TBI. Key features and goals of the 12 weekly CBT lessons included stigma minimization, personal engagement, and 1-2 hours per week of personal challenge homework assignments. We performed a randomized controlled trial initially involving military service members and veterans. Inclusion criteria were later relaxed to allow for civilian participation due to practical constraints . The control group received an app providing educational lessons about concussions and depression which did not include the therapeutic components of CBT. There was no difference between the groups randomized to CBT-D (n=19) vs. educational app control (n=23) in self-reported depression symptoms. Nevertheless, there was a statistically significant benefit of the CBT-D intervention in self-reported insomnia severity at the 16-week follow-up (four weeks post intervention) assessment (Cohens D=0.45, p=0.0064). There were also statistically significant positive correlations (r= 0.46 to 0.76, p=0.046 to 0.001) between changes over time in depression symptoms and changes over time in both insomnia and PTSD symptoms in the CBT-D group. There were no such correlations in the control group. Participants reported higher therapeutic alliance (p=0.0001) and overall mobile application user rating (p=0.036) for the CBT-D app than for the control education app. More favorable therapeutic alliance and mobile application user ratings correlated significantly with greater improvements in depression symptoms in the CBT-D group (r=0.53 to 0.66, p=0.02 to 0.002). However, dropout was substantial (40/59 in the CBT-D group and 31/54 in the control group) and results may not be fully representative of the population at risk. Conclusions: There remains a major unmet need for widely available, low-cost, effective interventions for depression symptoms in the context of mild TBI. The challenges of designing and rigorously assessing the effects such interventions remain formidable. However, the lessons learned from this study and indications of benefit in a highly relevant secondary outcome measure (insomnia) suggest that remote app-based interventions remain therapeutically viable. Trial Registration: clinicaltrials.gov NCT05147506, submitted 20 July 2021, posted 7 December 2021.

Objective: To identify demographic and daily cognitive, affective, and contextual predictors of headache-related interference with activity and concentration in a smartphone-based migraine cohort, using statistical models appropriate to the ordinal structure of patient-reported interference. Background: Migraine burden extends beyond headache to encompass cognitive and affective disturbance, yet most disability instruments summarize functioning retrospectively and cannot capture day-to-day variability in interference. Ecological momentary assessment addresses this limitation, yet few studies have examined cognitive and affective correlates of interference independent of pain intensity or have modeled interference using methods that respect its ordinal, non-equal-interval structure. Methods: From May 2025 to April 2026, adult participants were enrolled in this prospective, decentralized observational study via specialty clinics and social media campaigns. Eligibility required fulfilling ICHD-3 diagnostic criteria for migraine using a validated electronic survey and experiencing between 3 and 20 monthly headache days. Enrolled individuals recorded daily smartphone diary entries and performed three brief cognitive tests over a 30-day monitoring period. Daily interference with activities and concentration were captured on 5-point ordinal scales and analyzed via cumulative link mixed-effects models incorporating participant-specific random intercepts. Predictor selection across nested specifications relied on likelihood ratio testing and Akaike Information Criterion (AIC) metrics, prioritizing the more parsimonious model when goodness-of-fit was comparable. Results: The analytic sample comprised 1,267 headache-day observations from 143 participants. In the final models, brain fog (OR = 2.49 for activity, 3.19 for concentration), forgetfulness (OR = 1.48, 1.65), and mood disturbance (OR = 1.19, 1.31) were each independently associated with both outcomes (all p < 0.01), while age, sex, and employment status showed no significant association with either. Sleep quality (OR = 0.86) and anticipated next-day enjoyment (OR = 0.81) provided additional explanatory value for activity interference (p < 0.05) but not for concentration interference, for which the three-predictor model of brain fog, forgetfulness, and mood alone was retained as the most parsimonious final model. Conclusions: Cognitive and affective symptoms, rather than demographic or socioeconomic characteristics, are the primary correlates of headache-related functional interference in this cohort. Activity and concentration interference are explained by partially distinct sets of daily influences, supporting the clinical value of assessing cognitive and affective symptoms alongside conventional pain-focused evaluation.

Background: Stroke survivors frequently experience post-stroke depression (PSD) and post-stroke anxiety (PSA), which may be underexamined by clinicians if patient mood status between discharge and follow-up is unknown. Digital monitoring may enable early identification of mood disturbances. Ecological momentary assessments (EMA) have been tested to capture mood fluctuations in patients regular environments, but no standardized procedure for monitoring PSA or PSD has been developed. Objective: Determine the feasibility and validity of EMA for evaluating subacute PSA and PSD in non-severe stroke patients. Methods: Patients with non-severe stroke discharged home responded to daily smartphone EMA questions concerning mood and activity for twelve weeks until follow-up. Questions based on symptoms of anxiety and depression were used to derive EMA Anx and EMA Dep indices, computed over five 15-day intervals. Convergent validity was assessed using follow-up Generalized Anxiety Disorder-7 (GAD-7) and Centre for Epidemiological Studies-Depression (CES-D) scores. Logistic regression models predicted PSA and PSD status at follow-up, with baseline models comprising stroke severity, age, sex, and mood status, to which EMA Anx or Dep were added. Results: Data from 118 patients were analyzed. EMA adherence was moderate, with 89 patients (75.4%) responding on 75 or more days. Correlations between EMA Anx and GAD-7 and between EMA Dep and CES-D generally strengthened at later intervals, with the average mood index generally showing the strongest associations. Adding EMA data from the third time interval (31-45 days) significantly improved model fit beyond the baseline models (Anxiety: {chi}-square = 7.08, p = 0.008, {delta}R-square = 0.060; Depression: {chi}-square = 28.0, p < 0.001, {delta}R-square = 0.256). Discussion: EMA is feasible in mild-to-moderate stroke patients and may facilitate early identification of post-stroke mood disturbances. Further analyses in more diverse populations are required to validate these findings.

Background: Chronic musculoskeletal pain (CMP) is a common and debilitating symptom of Long COVID (LC), which shares several clinical features with Fibromyalgia Syndrome (FMS). Aims: This longitudinal study investigated whether the symptom overlap between LC-CMP and FMS persists over time, whether patterns differ according to pre-COVID CMP history, and the extent to which neuropathic pain features are present. Methods: Individuals with LC completed questionnaires assessing the symptom-based component of the 2010 American College of Rheumatology criteria for FMS and the presence of neuropathic pain features (PainDetect Questionnaire, PDQ) at baseline, 6- and 12-month follow-ups. Participants were grouped according to pre-COVID CMP history. Group differences were analysed using mixed-effects logistic regression. Results: 240 individuals completed the baseline assessment at a mean of 2.61 years after LC onset, including 131 (100 females) with new-onset CMP and 94 (87 females) with pre-existing CMP. The prevalence of participants meeting the symptom-based criteria for FMS remained high across follow-up (67.5-78.6%), with 50.0-61.0% of those with complete follow-up data fulfilling criteria at all timepoints. No significant subgroup differences were observed (OR = 0.43, 95% CI [0.14 1.39], p = 0.160). Across follow-up, 22.2-36.1% of participants reported likely neuropathic pain features, with significantly higher odds in the pre-existing CMP group (OR = 3.17, 95% CI [1.22 8.18], p = 0.017). Conclusions: FMS-like symptoms remain highly prevalent several years after acute COVID-19 and persist over a further 12 months, suggesting that LC-CMP frequently represents a persistent long-term condition with substantial overlap with FMS. These findings support closer integration of LC and chronic pain rehabilitation services and add to the wider literature linking post-infectious processes with FMS-like symptoms.

Non-pharmacological adjuncts are needed for chronic non-cancer pain in patients receiving long-term opioid therapy. Music listening may reduce pain, but most previous trials have used passive controls, limiting attribution of effects specifically to music. In this open-label, parallel- group, proof-of-concept randomized controlled trial, adults with chronic non-cancer pain receiving long-term opioid therapy were randomized 1:1 to four weeks of daily home-based music or audiobook listening. Analgesic outcomes included pain intensity, responder rates, quantity of pain relief, and multidimensional pain assessment; secondary outcomes included mood, quality of life, global impression of change, and safety. Of 70 participants entering the run-in period, 56 were randomized (28 per group). Adjusting for baseline pain intensity in a linear mixed-effects model, the between-group difference at end of treatment was -1.26 NRS points (95% CI -1.98 to -0.55; p<0.001; d=-0.70), favoring music. A [&ge;]30% pain-reduction criterion was met by 21.4% of participants in the music group and none in the audiobook group (p=0.023). An exploratory between-group difference in pain intensity favoring music was also observed at follow-up. Other analgesic and secondary outcomes showed no significant between-group differences, although exploratory within-group improvements in mood and health-related quality of life were observed with music. Both groups reported overall improvement in global perceived change, with ratings numerically favoring music. No intervention-related harms were observed. These findings support an analgesic benefit of music beyond the structured listening experience shared with the active comparator. Daily self-administered music listening may represent a feasible, low-cost adjunct for chronic non-cancer pain in patients receiving long-term opioid therapy.

Background Chronic subdural hematoma (CSDH) is common and increasing in incidence. Short-term post-surgical outcomes are good, but longer term, patients experience increased morbidity and early mortality than controls and the general population. Deprivation and ethnicity affect many health conditions, but to our knowledge, this is the first UK study investigating their association with CSDH outcomes. Methods This single-centre retrospective cohort study used Secondary Uses Service Admitted Patient Care Spells (SUS+ APCS) data. Adult subdural hematoma (SDH) patients admitted to St Georges Hospital, London treated with burr-hole surgery between April 2022 and April 2025 were included. Primary outcomes were initial length of stay (LoS) and days spent hospitalised in the subsequent year. Deprivation was measured using Index of Multiple Deprivation (IMD). Linear regression models estimated initial LoS and subsequent days spent hospitalised by category, adjusted for factors including age, ethnicity and comorbidities. Results In this single-centre cohort of 449 patients, IMD was not associated with initial LoS, but was significantly associated with subsequent time spent hospitalised. In a log-transformed linear regression model, the most deprived spent 4.5-times longer hospitalised during the year after CSDH than the least deprived (fold change = 4.45, 95% confidence interval (95%CI) 2.20 to 9.01). Conclusions Higher neighbourhood-level deprivation was associated with time spent hospitalised following CSDH. This was robust to adjustment for potential mediating factors. This is the first UK study demonstrating health inequalities in CSDH outcomes, highlighting a need for future research to gain further insights, and to improve equity of outcomes after CSDH.

Introduction: Neuroinflammation is a known pathophysiologic mechanism in multiple sclerosis and a proposed mechanism in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Positron Emission Tomography (PET) imaging of the translocator protein (TSPO) has been widely used to measure neuroinflammation, though second-generation ligands are highly sensitive to a single nucleotide polymorphism, rs6971, resulting in high, mixed, and low affinity binders. It is unknown whether this polymorphism is associated with neuroinflammatory disorders. Materials and Methods: Eighty-six total participant genotypes for TSPO binding affinity were identified through Sanger sequencing (30 fibromyalgia, 21 ME/CFS, 11 multiple sclerosis, and 24 healthy controls). Associations between patient group and genotype were assessed with Fishers Exact test. Associations between genotype and symptom severity from self-report questionnaires were assessed with Kruskal-Wallis tests. Results: In the present study individuals with fibromyalgia, (ME/CFS), or multiple sclerosis were more likely to have a mixed- or low-affinity genotypes compared to healthy controls. Presence of the low or mixed genotypes were also associated with greater self-reported fatigue severity and depressive symptoms. Discussion: These findings should be confirmed in larger samples but suggest functional consequences of rs6971 polymorphism that may be related to the pathophysiology of pain and fatigue illnesses.

Background: Relapsing-remitting multiple sclerosis (RRMS) often progresses to secondary-progressive MS (SPMS), but diagnosis is typically retrospective, delaying potential interventions. Existing rule-based and machine learning approaches often lack prospective validation and provide no uncertainty estimates, limiting clinical adoption. Objective: To prospectively evaluate a conformal prediction (CP)-enabled random forest model for reproducing clinician-recorded disease course labels in the Swedish Multiple Sclerosis Registry (SMSReg) and compare its classifications with the Lorscheider criteria. Methods: The CP model was trained and calibrated on SMSReg-2022 (10,787 individuals, 85,461 hospital visits) and then validated on SMSReg-2025 (15,719 individuals, 45,077 hospital visits; not included in the SMSReg-2022 training/calibration/testing datasets). Performance was assessed at the hospital visit and individual levels and compared with the Lorscheider criteria. Results: The model maintained good calibration on the prospective dataset. At the per-hospital visit-level, the model accuracies were 92% (RRMS) and 95% (SPMS). At the individual level, sensitivity was 98%, specificity 89%, and F1-score 0.75. With clinician-recorded labels as reference, the model showed higher sensitivity than the Lorscheider criteria (98% vs. 71%), more transition assignments (90% vs. 57%), and higher F1-score (0.76 vs. 0.69). Conclusion: The CP-enabled model prospectively reproduced clinician-recorded disease course labels with calibrated uncertainty, supporting harmonization and decision support.

Background: Dexmedetomidine (DEX) and midazolam (MDZ) are commonly used agents for conscious sedation in patients with acute ischemic stroke (AIS) treated with endovascular thrombectomy (EVT). While DEX offers superior sedation quality and potential neuroprotective effects, it is also associated with risk of hemodynamic instability. High-quality evidence directly comparing their impact on functional outcomes after EVT is lacking. This trial aims to determine whether conscious sedation with DEX, compared to MDZ, improves functional outcomes in patients with AIS due to anterior circulation large vessel occlusion (LVO) undergoing EVT. Methods: PEACE (Dexmedetomidine versus Midazolam for Conscious Sedation during Endovascular Stroke Thrombectomy) is a prospective, randomized, open label, blinded-endpoint, multicenter trial. Up to 810 patients with AIS due to LVO in the anterior circulation within 24 hours of last known well will be randomly assigned in a 1:1 ratio to receive either DEX or MDZ for conscious sedation during EVT across 30 centers in China. Results: The primary end point is the proportion of patients achieving a modified Rankin Scale (mRS) score 0-2 at 90 days, analyzed in the intention-to-treat population using a modified Poisson regression model, with results expressed as a risk ratio. Key secondary outcomes include the ordinal distribution of mRS scores at 90 days, and successful recanalization. Safety outcomes include symptomatic intracranial hemorrhage within 48 hours, and mortality at 90 days. Conclusion: The PEACE trial will provide definitive, high-level evidence on the comparative efficacy and safety of DEX versus MDZ for conscious sedation during EVT in patients with AIS due to LVO in the anterior circulation, with the goal of guiding clinical practice.

BackgroundPersistent postural-perceptual dizziness (PPPD) is a chronic functional dizziness disorder characterized by unsteadiness, hypersensitivity to motion and visually complex environments. Although increasingly investigated, the role of the different factors involved remains unclear. This study aims to comprehensively characterize PPPD across clinical, biological, and behavioral domains. MethodsData from 18 PPPD patients and 20 age- and sex-matched healthy control volunteers (HC) were analyzed, including clinical and psychological questionnaires, a neuropsychological battery, salivary markers, posturography under different conditions, and gait analysis under single- and dual-task demands. ResultsPatients reported greater depressive symptoms, higher perceived stress, and reduced quality of life than HC, but showed no neuropsychological deficits and comparable past psychological trauma and personality traits. Salivary stress marker levels were similar to HC. Gait analysis revealed a slower, cautious gait in patients, which worsened without vision, with no differences in automaticity (stride time variability). Postural assessments showed greater sway and enhanced low-frequency oscillations, exacerbated by absence of visual input in PPPD. Visual reliance for postural control correlated negatively with subjective symptom severity, but not other symptom-related measures. ConclusionPPPD patients have lower mood and increased perceived stress, with no increase in biological stress markers compared to HC. Cognition, personality, and exposure to past trauma might be less relevant than previously hypothesized. Patients show visual dependence for gait and postural control, likely a maladaptive compensatory mechanism. These findings support interventions targeted at reducing visual dependence and at improving mood, rather than interventions focusing on psychological trauma. SummaryO_LIWhat is already known on this topic - PPPD (Persistent Perceptual Postural Dizziness) is a functional dizziness disorder characterized by different biopsychosocial factors, often investigated in isolation. C_LIO_LIWhat this study adds - PPPD patients have higher depression and perceived stress scores, lower quality of life, but show no differences in past trauma, personality traits, and biological stress markers, compared to healthy controls. They also show a reliance on vision both for gait and for postural control, with increased low-frequency oscillations in the anteroposterior direction. Visual dependence is likely maintained by its perceived role in symptom reduction. C_LIO_LIHow this study might affect research, practice or policy - These findings support rehabilitation strategies aimed at reducing reliance on vision and increasing reliance on vestibular inputs, but not interventions focusing on past traumatic experiences. C_LI

Background: Temporomandibular disorders (TMDs) are common conditions in the general population. Several therapeutic approaches are available, but there is no consensus on the most effective, particularly in physiotherapy. Objectives: To assess the efficacy of manual therapy (MT) and therapeutic exercise (TE) in reducing pain in patients with TMDs. Methods: Four databases (MEDLINE, PEDro, EMBASE, CINAHL) were searched up to March 2025. We included randomized controlled trials (RCTs) evaluating the effects of MT and/or TE in individuals with TMDs, compared to any other rehabilitation treatment, with pain intensity as the primary outcome. The methodological quality was assessed using the PEDro scale. A network meta-analysis was performed to compare the effectiveness of different rehabilitative approaches. Results: 25 RCTs for a total of 1,540 people were included. The main comparisons were: MT and/or TE vs no treatment or placebo, occlusal splint, and instrumental physiotherapy. In most studies, MT and TE were more effective than controls in reducing pain. However, the network meta-analysis indicated that multimodal treatments were the most effective. The methodological quality of the included studies ranged from 3 to 9 points. Conclusion: MT and TE are effective strategies for reducing pain in subjects with TMDs and should be used as first-line interventions before more invasive treatments; the combination of dry needling and manual therapy appears to be the most effective approach. Nonetheless, the variability in study quality suggests that further high-quality research is needed to confirm these findings.

Word-finding difficulty (tip-of-the-tongue phenomenon) is among the most prevalent changes reported by persons with multiple sclerosis (MS), but we lack validated performance metrics to assess this common symptom. Antonyms is a novel task evaluating retrieval of target phonological codes via a brief, clinically-feasible paradigm that controls for other cognitive processes. Test-retest reliability was good (0.85). Among 660 patients, Antonyms demonstrated better criterion validity than traditional language tasks (e.g., animal generation, Boston Naming Test). Demonstrating discriminate validity, Antonyms was specifically related to patient-reported difficulties with expressive language rather than working memory, executive/speed, or episodic memory. The Antonyms task is provided herein.

Abstract Background: Despite the high stroke burden in the elderly, their thrombolysis utilization is suboptimal partly due to heightened hemorrhagic risk. Observational data suggest that low-dose thrombolysis may offer comparable efficacy to standard-dose with a trend toward reduced symptomatic intracranial hemorrhage (sICH), yet high-level evidence for low-dose thrombolysis in this broad population remains absent. Objective: To evaluate the safety and efficacy of low-dose intravenous tenecteplase thrombolysis in elderly stroke patients within 4.5 hours of ischaemic stroke onset. Methods and design: The DATE-AGING trial is a multicenter, prospective, randomized, open-label, blinded-end point (PROBE) non-inferiority study. Eligible participants are elderly patients (aged [&ge;]70 years)with acute ischemic stroke who meet current guideline recommendations for intravenous thrombolysis within 4.5 hours of symptom onset will be randomly assigned to Low-dose Tenecteplase group (0.175 mg/kg, max 17.5 mg) or Standard-dose Tenecteplase group (0.25 mg/kg, max 25 mg). The primary outcome was excellent functional outcome, defined as a mRS 0-1 assessed at 90-day post-randomization. Safety outcomes included sICH within 36 hours and mortality at 90 days. Discussions: The DATE-AGING trial is intended to provide high-quality evidence for low-dose tenecteplase intravenous thrombolysis in elderly patients with acute ischemic stroke. Trial registry number: NCT07294209(https://clinicaltrials.gov/study/07294209). Keywords: elderly patients, acute ischemic stroke, intravenous thrombolysis, low-dose tenecteplase

Background/Aims: Pre-stroke depression has been shown to be associated with worse functional outcomes and depression after stroke. However, it is not currently well understood whether pre-stroke mood disorders (e.g., depression, anxiety, mood and psychotic disorders, substance use disorder) are associated with withdrawal of life-sustaining treatment (WOLST) after a severe stroke. Methods: This was a retrospective cohort study within the Tufts Vascular Neurology Registry of patients hospitalized with severe acute ischemic stroke (AIS, defined as NIHSS [&ge;]10) or severe nontraumatic intracerebral hemorrhage (ICH, defined as ICH score [&ge;]2) between 2018 and 2022. Multivariate logistic regression was performed to identify predictors of WOLST. Results: This study included 405 patients with severe stroke. Patients who opted for WOLST were more likely to be older, female, have AIS, and experience more severe strokes. In an adjusted analysis (basic demographics, stroke type), a pre-stroke mood disorder was associated with WOLST (OR 2.15, 95% CI 1.11-4.15). In models stratified by stroke type (AIS vs. ICH) and adjusted for stroke severity, WOLST was associated with age in both groups and with mood disorder in patients with ICH. The WOLST event rate was higher in the ICH group (19% vs 11%). Conclusion: Pre-stroke mood disorder was associated with increased rates of withdrawal of care after severe stroke in this patient population. Opportunities to actively treat depression may be useful to include in goals of care discussions to mitigate the potential impact of this factor in decision-making. Consistent with prior studies, we observed a higher proportion of WOLST in older, female, and ICH patients. Future studies regarding the quality and content of goals of care discussions may help elucidate the differing effects of pre-stroke mood disorders on WOLST by stroke type seen in this study.

BackgroundNeuropathic pain is a common and debilitating condition with persistently poor translation from preclinical research to effective clinical therapies. Preclinical systematic reviews and meta-analyses (SRMAs) can provide more robust estimates of intervention effects and help identify sources of bias and heterogeneity, but their use is limited by the time and effort required to synthesise rapidly expanding literatures. Automation may help overcome these barriers. MethodsWe developed Neuropathic Pain - Systematic Online Living Evidence Summaries (NP-SOLES), a machine-assisted approach used in this study to support systematic identification of animal studies relevant to neuropathic pain. Using NP-SOLES, we conducted a pilot systematic review and meta-analysis of controlled animal studies assessing the effects of citrus flavonoids on thermal and mechanical pain-related outcomes in streptozotocin-induced models of painful diabetic neuropathy. ResultsIn this pilot application, machine-assisted evidence synthesis supported reduced manual screening burden, illustrating the potential of such approaches to facilitate timely preclinical SRMAs. Fourteen studies met inclusion criteria for meta-analysis on thermal pain-related outcomes. Pooled estimates suggested a reduction in thermal pain-related behaviours following flavonoid treatment; however, substantial heterogeneity and widespread methodological limitations were observed. Nine studies were eligible for qualitative analysis on mechanical pain-related outcomes, which showed an overall reduction in pain-related behaviours following treatment but had similar methodological limitations. Reporting of key measures to reduce risk of bias, including randomisation and blinding, were consistently poor, and subgroup analyses were constrained by sparse data. ConclusionsAvailable evidence from preclinical animal studies suggests a potential analgesic effect of citrus flavonoids on thermal and mechanical pain-related outcomes in diabetic neuropathy models, but confidence in this estimate is limited by significant risks of bias. More rigorously designed and transparently reported preclinical studies are required before clinical translation can be justified.

Background: Although opioids are frequently prescribed for refractory chronic neuropathic pain, few data are available on baseline factors that may identify individuals more likely to respond and inform individually tailored practice. Methods: This was a post hoc, exploratory analysis of individual-level data from a placebo-controlled trial of methadone for chronic neuropathic pain (NCT05235191). Baseline clinical, psychological, psychophysical and radiological variables were tested for association with 30% or more pain reduction in the methadone group. The correlation between expectation of improvement and pain reduction was examined in both groups. Results: Of the 81 participants completing the 8-week follow-up, 28 (70%) on methadone and 14 (34.1%) on placebo achieved 30% or more pain reduction. In the methadone group, responders had higher baseline expectation of improvement (median 100 [80-100] vs. 55 [50-81]; p=0.004), which correlated moderately with percentage pain reduction (rs=0.508; p<0.001). Neither finding was observed in the placebo group (p=0.211 and p=0.161, respectively), although the correlation did not differ significantly between groups (p for interaction=0.728). Other clinical, sociodemographic, psychological and psychophysical variables were not associated with response. In the subsample with peripheral neuropathic pain and structural MRI (n=37), lower left precentral cortex volume was associated with response to methadone (p=0.041), and lower right paracentral volume with response to placebo (p=0.003). Conclusions: Baseline expectation may influence treatment outcomes, supporting its inclusion as a covariate to improve the precision of treatment effect estimates in trials, and its use in clinical practice to help tailor treatment to individual patients. These exploratory findings require confirmation in larger studies.